Literature DB >> 23620181

Protective effects of Lactobacillus rhamnosus GG against human rotavirus-induced diarrhoea in a neonatal mouse model.

Zhen Zhang1, Yun Xiang, Na Li, Baoxiang Wang, Hongwu Ai, Xiaomei Wang, Laiqiang Huang, Yi Zheng.   

Abstract

Group A human rotaviruses (RV) are a leading cause of severe dehydration and gastroenteritis in infants and young children. A large body of evidence suggests that Lactobacillus rhamnosus GG (LGG) has an effect on the incidence and severity of acute RV-induced diarrhoea; however, the timing and dosage of LGG treatment remains controversial. In the present study, a neonatal mouse model with human RV-induced diarrhoea was set up and the pathophysiological characteristics of the animals were examined. Our results indicated that RV-infected mice developed diarrhoea, accompanied by increased secretion of intestinal mucosa sIgA and serum interferon (IFN)-γ, tumour necrosis factor (TNF)-α, as well as decreased serum IgA. In addition, epithelium vacuolation was noticed in the jejunum microvillus of RV-infected mice. After intragastric administration of low (2 × 10(5) CFU), middle (2 × 10(7) CFU) or high (2 × 10(9) CFU) levels of LGG for four consecutive days before or after RV infection respectively, the RV-infected mice showed a shortened duration of diarrhoea and decreased epithelium vacuolation in the jejunum. Administration of a high dose of LGG before the RV infection was found to have better protective effects against RV infection than other regimens. This study demonstrates that the protective effects of LGG against RV-induced diarrhoea are highly correlated with the timing and dosage of LGG administration in neonatal mice.
© 2013 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23620181     DOI: 10.1111/2049-632X.12030

Source DB:  PubMed          Journal:  Pathog Dis        ISSN: 2049-632X            Impact factor:   3.166


  8 in total

Review 1.  Pathogen-induced secretory diarrhea and its prevention.

Authors:  S Anand; S Mandal; P Patil; S K Tomar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-29       Impact factor: 3.267

Review 2.  Combined use of lactic-acid-producing bacteria as probiotics and rotavirus vaccine candidates expressing virus-specific proteins.

Authors:  Atefeh Afchangi; Tayebeh Latifi; Somayeh Jalilvand; Sayed Mahdi Marashi; Zabihollah Shoja
Journal:  Arch Virol       Date:  2021-02-03       Impact factor: 2.574

3.  A combination of scGOS/lcFOS with Bifidobacterium breve M-16V protects suckling rats from rotavirus gastroenteritis.

Authors:  M Rigo-Adrover; S Saldaña-Ruíz; K van Limpt; K Knipping; J Garssen; J Knol; A Franch; M Castell; F J Pérez-Cano
Journal:  Eur J Nutr       Date:  2016-04-25       Impact factor: 5.614

Review 4.  Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

5.  Dietary Lactobacillus rhamnosus GG Supplementation Improves the Mucosal Barrier Function in the Intestine of Weaned Piglets Challenged by Porcine Rotavirus.

Authors:  Xiangbing Mao; Changsong Gu; Haiyan Hu; Jun Tang; Daiwen Chen; Bing Yu; Jun He; Jie Yu; Junqiu Luo; Gang Tian
Journal:  PLoS One       Date:  2016-01-04       Impact factor: 3.240

6.  Oral administration of Bifidobacterium bifidum G9-1 alleviates rotavirus gastroenteritis through regulation of intestinal homeostasis by inducing mucosal protective factors.

Authors:  Tomohiro Kawahara; Yutaka Makizaki; Yosuke Oikawa; Yoshiki Tanaka; Ayako Maeda; Masaki Shimakawa; Satoshi Komoto; Kyoko Moriguchi; Hiroshi Ohno; Koki Taniguchi
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240

7.  High protective efficacy of rice bran against human rotavirus diarrhea via enhancing probiotic growth, gut barrier function, and innate immunity.

Authors:  Xingdong Yang; Erica Twitchell; Guohua Li; Ke Wen; Mariah Weiss; Jacob Kocher; Shaohua Lei; Ashwin Ramesh; Elizabeth P Ryan; Lijuan Yuan
Journal:  Sci Rep       Date:  2015-10-13       Impact factor: 4.379

8.  Anti-VP6 VHH: An Experimental Treatment for Rotavirus A-Associated Disease.

Authors:  Lucía Maffey; Celina G Vega; Samuel Miño; Lorena Garaicoechea; Viviana Parreño
Journal:  PLoS One       Date:  2016-09-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.